Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and Long-Term Outcomes of a Single-Blind Randomized Study

Autor:	Stephen R. Wisniewski, Diane Warden, Benji T. Kurian, Ian A. Cook, Mustafa M. Husain, Richard C. Shelton, James F. Luther, Andrew A. Nierenberg, Madhukar H. Trivedi, Jonathan W. Stewart, A. John Rush, Susan G. Kornstein, Ira M. Lesser, David W. Morris, Maurizio Fava
Rok vydání:	2012
Předmět:	Bupropion medicine.medical_specialty Side effect business.industry Serotonin reuptake inhibitor Mirtazapine Venlafaxine Placebo law.invention Psychiatry and Mental health Randomized controlled trial law Internal medicine medicine Escitalopram business Psychiatry medicine.drug
Zdroj:	FOCUS. 10:492-505
ISSN:	1541-4108 1541-4094
Popis:	Objective:Two antidepressant medication combinations were compared with selective serotonin reuptake inhibitor monotherapy to determine whether either combination produced a higher remission rate in first-step acute-phase (12 weeks) and long-term (7 months) treatment. Method:The single-blind, prospective, randomized trial enrolled 665 outpatients at six primary and nine psychiatric care sites. Participants had at least moderately severe nonpsychotic chronic and/or recurrent major depressive disorder. Escitalopram (up to 20 mg/day) plus placebo, sustained-release bupropion (up to 400 mg/day) plus escitalopram (up to 20 mg/day), or extended-release venlafaxine (up to 300 mg/day) plus mirtazapine (up to 45 mg/day) was delivered (1:1:1 ratio) by using measurement-based care. The primary outcome was remission, defined as ratings of less than 8 and less than 6 on the last two consecutive applications of the 16-item Quick Inventory of Depressive Symptomatology—Self-Report. Secondary outcomes included side effect...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62575bfe6150ef9d42f4d523e7cb74c9 https://doi.org/10.1176/appi.focus.10.4.492 Zobrazit plný text záznamu